Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2020 | Nov. 05, 2020 | |
Document Information [Line Items] | ||
Entity Registrant Name | GeoVax Labs, Inc. | |
Entity Central Index Key | 0000832489 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Non-accelerated Filer | |
Entity Current Reporting Status | Yes | |
Entity Emerging Growth Company | false | |
Entity Small Business | true | |
Entity Interactive Data Current | Yes | |
Entity Common Stock, Shares Outstanding (in shares) | 3,810,836 | |
Entity Shell Company | false | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2020 | |
Document Fiscal Year Focus | 2020 | |
Document Fiscal Period Focus | Q3 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
ASSETS | ||
Cash and cash equivalents | $ 11,580,594 | $ 283,341 |
Grant funds and other receivables | 141,154 | 68,603 |
Prepaid expenses and other current assets | 13,046 | 95,320 |
Total current assets | 11,734,794 | 447,264 |
Property and equipment, net (Note 5) | 10,093 | 10,606 |
Deposits | 11,010 | 11,010 |
Total assets | 11,755,897 | 468,880 |
Current liabilities: | ||
Accounts payable | 161,478 | 152,653 |
Accrued expenses (Note 6) | 579,585 | 1,851,040 |
Current portion of notes payable | 182,584 | 12,500 |
Total current liabilities | 923,647 | 2,016,193 |
Note payable, net of current portion | 18,506 | 27,243 |
Total liabilities | 942,153 | 2,043,436 |
Commitments (Note 9) | ||
Stockholders’ equity (deficiency): | ||
Preferred Stock, $.01 par value (Note 10): Authorized shares – 10,000,000 Issued and outstanding shares – 400 and 2,486 June 30, 2020 and December 31, 2019, respectively | 76,095 | 1,932,433 |
Common stock, $.001 par value: Authorized shares – 600,000,000 Issued and outstanding shares – 13,834,075 and 299,835 at June 30, 2020 and December 31, 2019, respectively | 3,559 | 15 |
Additional paid-in capital | 55,203,149 | 39,340,509 |
Accumulated deficit | (44,469,059) | (42,847,513) |
Total stockholders’ equity (deficiency) | 10,813,744 | (1,574,556) |
Total liabilities and stockholders’ equity (deficiency) | $ 11,755,897 | $ 468,880 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Sep. 30, 2020 | Dec. 31, 2019 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 100 | 2,486 |
Preferred stock, shares outstanding (in shares) | 100 | 2,486 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 600,000,000 | 600,000,000 |
Common stock, shares issued (in shares) | 3,559,473 | 14,992 |
Common stock, shares outstanding (in shares) | 3,559,473 | 14,992 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Grant and collaboration revenue | $ 415,458 | $ 333,209 | $ 1,572,037 | $ 907,382 |
Operating expenses: | ||||
Research and development | 416,756 | 467,674 | 1,687,113 | 1,474,619 |
General and administrative | 435,013 | 291,475 | 1,364,650 | 1,214,189 |
Total operating expenses | 851,769 | 759,149 | 3,051,763 | 2,688,808 |
Loss from operations | (436,311) | (425,940) | (1,479,726) | (1,781,426) |
Other income (expense): | ||||
Interest income | 90 | 2,560 | 902 | 4,665 |
Interest expense | (134,427) | (1,054) | (142,722) | (3,275) |
Total other income (expense) | (134,337) | 1,506 | (141,820) | 1,390 |
Net loss | $ (570,648) | $ (424,434) | $ (1,621,546) | $ (1,780,036) |
Basic and diluted: | ||||
Net loss per common share (in dollars per share) | $ (0.73) | $ (1,282.28) | $ (2.85) | $ (14,016.03) |
Weighted average shares outstanding (in shares) | 782,978 | 331 | 569,955 | 127 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($) | Conversion from Convertible Debentures to Conversion Units [Member]Preferred Stock [Member] | Conversion from Convertible Debentures to Conversion Units [Member]Common Stock [Member] | Conversion from Convertible Debentures to Conversion Units [Member]Additional Paid-in Capital [Member] | Conversion from Convertible Debentures to Conversion Units [Member]Retained Earnings [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 3,450 | 11 | ||||||||
Balance at Dec. 31, 2018 | $ 1,971,333 | $ 37,483,204 | $ (40,476,884) | $ (1,022,347) | ||||||
Net loss | (701,454) | (701,454) | ||||||||
Balance at Mar. 31, 2019 | $ 2,072,108 | 37,899,081 | (41,178,338) | (1,207,149) | ||||||
Balance (in shares) at Dec. 31, 2018 | 3,450 | 11 | ||||||||
Balance at Dec. 31, 2018 | $ 1,971,333 | 37,483,204 | (40,476,884) | (1,022,347) | ||||||
Net loss | (1,780,036) | |||||||||
Balance at Sep. 30, 2019 | $ 2,321,823 | $ 3 | 38,914,375 | (42,256,920) | (1,020,719) | |||||
Balance (in shares) at Dec. 31, 2018 | 3,450 | 11 | ||||||||
Balance at Dec. 31, 2018 | $ 1,971,333 | 37,483,204 | (40,476,884) | (1,022,347) | ||||||
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 500 | |||||||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 404,250 | 85,750 | 490,000 | |||||||
Conversion of preferred stock to common stock (in shares) | (767) | 3 | ||||||||
Conversion of preferred stock to common stock | $ (303,475) | 303,475 | ||||||||
Net loss | ||||||||||
Balance at Mar. 31, 2020 | $ 376,095 | $ 690 | 41,202,172 | (43,443,207) | (1,864,250) | |||||
Balance (in shares) at Mar. 31, 2019 | 3,183 | 14 | ||||||||
Balance at Mar. 31, 2019 | $ 2,072,108 | 37,899,081 | (41,178,338) | (1,207,149) | ||||||
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 500 | |||||||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 438,700 | 61,300 | 500,000 | |||||||
Conversion of preferred stock to common stock (in shares) | (281) | 6 | ||||||||
Conversion of preferred stock to common stock | $ (172,941) | 172,941 | ||||||||
Common stock issued for services (in shares) | ||||||||||
Common stock issued for services | 6,000 | 6,000 | ||||||||
Net loss | (654,148) | (654,148) | ||||||||
Balance at Jun. 30, 2019 | $ 2,337,867 | 38,165,986 | (41,832,486) | (1,328,633) | ||||||
Balance (in shares) at Jun. 30, 2019 | 3,402 | 20 | ||||||||
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 700 | |||||||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 700,000 | 700,000 | ||||||||
Conversion of preferred stock to common stock (in shares) | (1,048) | 2,369 | ||||||||
Conversion of preferred stock to common stock | $ (716,044) | $ 3 | 716,041 | |||||||
Common stock issued for services (in shares) | 1 | |||||||||
Common stock issued for services | 6,000 | 6,000 | ||||||||
Net loss | (424,434) | (424,434) | ||||||||
Balance at Sep. 30, 2019 | $ 2,321,823 | $ 3 | 38,914,375 | (42,256,920) | (1,020,719) | |||||
Balance (in shares) at Dec. 31, 2019 | 2,486 | 14,992 | ||||||||
Balance at Dec. 31, 2019 | $ 1,932,433 | $ 15 | 39,340,509 | (42,847,513) | (1,574,556) | |||||
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 300 | |||||||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 300,000 | 300,000 | ||||||||
Conversion of preferred stock to common stock (in shares) | (2,386) | 674,067 | ||||||||
Conversion of preferred stock to common stock | $ (1,856,338) | $ 674 | 1,855,664 | |||||||
Common stock issued for services (in shares) | 521 | |||||||||
Common stock issued for services | $ 1 | 5,999 | 6,000 | |||||||
Net loss | (595,694) | (595,694) | ||||||||
Balance at Mar. 31, 2020 | $ 376,095 | $ 690 | 41,202,172 | (43,443,207) | (1,864,250) | |||||
Balance (in shares) at Dec. 31, 2019 | 2,486 | 14,992 | ||||||||
Balance at Dec. 31, 2019 | $ 1,932,433 | $ 15 | 39,340,509 | (42,847,513) | $ (1,574,556) | |||||
Common stock issued for services (in shares) | 3,162 | |||||||||
Net loss | $ (1,621,546) | |||||||||
Stock Issued During Period, Shares, Warrants Exercised | 36,902 | |||||||||
Stock Issued During Period, Shares, Cancellation of Accrued Compensation | 300,001 | |||||||||
Balance at Sep. 30, 2020 | $ 76,095 | $ 3,559 | 55,203,149 | (44,469,059) | $ 10,813,744 | |||||
Balance (in shares) at Mar. 31, 2020 | 400 | 689,580 | ||||||||
Balance at Mar. 31, 2020 | $ 376,095 | $ 690 | 41,202,172 | (43,443,207) | (1,864,250) | |||||
Common stock issued for services (in shares) | 2,124 | |||||||||
Common stock issued for services | $ 2 | 11,998 | 12,000 | |||||||
Net loss | (455,204) | (455,204) | ||||||||
Warrants issued in bridge financing | 457,833 | 457,833 | ||||||||
Balance at Jun. 30, 2020 | $ 376,095 | $ 692 | 41,672,003 | (43,898,411) | (1,849,621) | |||||
Balance (in shares) at Jun. 30, 2020 | 400 | 691,704 | ||||||||
Conversion of preferred stock to common stock (in shares) | 177,626 | (300) | 42,723 | |||||||
Conversion of preferred stock to common stock | $ 177 | $ 569,340 | $ 569,517 | $ (300,000) | $ 43 | 299,957 | ||||
Common stock issued for services (in shares) | 517 | |||||||||
Common stock issued for services | 6,000 | 6,000 | ||||||||
Net loss | (570,648) | (570,648) | ||||||||
Stock Issued During Period, Shares, Warrants Exercised | 36,902 | |||||||||
Warrants exercised for common stock | $ 37 | (37) | ||||||||
Stock Issued During Period, Shares, Cancellation of Accrued Compensation | 300,001 | |||||||||
Common stock issued upon cancellation of accrued compensation | $ 300 | 1,499,700 | 1,500,000 | |||||||
Sale of common stock for cash (in shares) | 2,310,000 | |||||||||
Sale of common stock for cash | $ 2,310 | 11,156,186 | 11,158,496 | |||||||
Balance at Sep. 30, 2020 | $ 76,095 | $ 3,559 | $ 55,203,149 | $ (44,469,059) | $ 10,813,744 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2018 | 3,450 | 11 | |||
Balance at Dec. 31, 2018 | $ 1,971,333 | $ 37,483,204 | $ (40,476,884) | $ (1,022,347) | |
Net loss | (701,454) | (701,454) | |||
Balance (in shares) at Mar. 31, 2019 | 3,183 | 14 | |||
Balance at Mar. 31, 2019 | $ 2,072,108 | 37,899,081 | (41,178,338) | (1,207,149) | |
Balance (in shares) at Dec. 31, 2018 | 3,450 | 11 | |||
Balance at Dec. 31, 2018 | $ 1,971,333 | 37,483,204 | (40,476,884) | (1,022,347) | |
Net loss | (1,780,036) | ||||
Balance (in shares) at Sep. 30, 2019 | 3,054 | 2,390 | |||
Balance at Sep. 30, 2019 | $ 2,321,823 | $ 3 | 38,914,375 | (42,256,920) | (1,020,719) |
Balance (in shares) at Dec. 31, 2018 | 3,450 | 11 | |||
Balance at Dec. 31, 2018 | $ 1,971,333 | 37,483,204 | (40,476,884) | (1,022,347) | |
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 500 | ||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 404,250 | 85,750 | 490,000 | ||
Conversion of preferred stock to common stock (in shares) | (767) | 3 | |||
Conversion of preferred stock to common stock | $ (303,475) | 303,475 | |||
Stock option expense | 26,652 | 26,652 | |||
Net loss | |||||
Balance (in shares) at Mar. 31, 2020 | 400 | 689,580 | |||
Balance at Mar. 31, 2020 | $ 376,095 | $ 690 | 41,202,172 | (43,443,207) | (1,864,250) |
Balance (in shares) at Mar. 31, 2019 | 3,183 | 14 | |||
Balance at Mar. 31, 2019 | $ 2,072,108 | 37,899,081 | (41,178,338) | (1,207,149) | |
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 500 | ||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 438,700 | 61,300 | 500,000 | ||
Conversion of preferred stock to common stock (in shares) | (281) | 6 | |||
Conversion of preferred stock to common stock | $ (172,941) | 172,941 | |||
Stock option expense | 26,664 | 26,664 | |||
Net loss | (654,148) | (654,148) | |||
Common stock issued for services (in shares) | |||||
Common stock issued for services | 6,000 | 6,000 | |||
Balance (in shares) at Jun. 30, 2019 | 3,402 | 20 | |||
Balance at Jun. 30, 2019 | $ 2,337,867 | 38,165,986 | (41,832,486) | (1,328,633) | |
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 700 | ||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 700,000 | 700,000 | |||
Conversion of preferred stock to common stock (in shares) | (1,048) | 2,369 | |||
Conversion of preferred stock to common stock | $ (716,044) | $ 3 | 716,041 | ||
Stock option expense | 26,348 | 26,348 | |||
Net loss | (424,434) | (424,434) | |||
Common stock issued for services (in shares) | 1 | ||||
Common stock issued for services | 6,000 | 6,000 | |||
Balance (in shares) at Sep. 30, 2019 | 3,054 | 2,390 | |||
Balance at Sep. 30, 2019 | $ 2,321,823 | $ 3 | 38,914,375 | (42,256,920) | (1,020,719) |
Balance (in shares) at Dec. 31, 2019 | 2,486 | 14,992 | |||
Balance at Dec. 31, 2019 | $ 1,932,433 | $ 15 | 39,340,509 | (42,847,513) | (1,574,556) |
Sale of convertible preferred stock for cash and cancellation of note payable (in shares) | 300 | ||||
Sale of convertible preferred stock for cash and cancellation of note payable | $ 300,000 | 300,000 | |||
Conversion of preferred stock to common stock (in shares) | (2,386) | 674,067 | |||
Conversion of preferred stock to common stock | $ (1,856,338) | $ 674 | 1,855,664 | ||
Net loss | (595,694) | (595,694) | |||
Common stock issued for services (in shares) | 521 | ||||
Common stock issued for services | $ 1 | 5,999 | 6,000 | ||
Balance (in shares) at Mar. 31, 2020 | 400 | 689,580 | |||
Balance at Mar. 31, 2020 | $ 376,095 | $ 690 | 41,202,172 | (43,443,207) | (1,864,250) |
Balance (in shares) at Dec. 31, 2019 | 2,486 | 14,992 | |||
Balance at Dec. 31, 2019 | $ 1,932,433 | $ 15 | 39,340,509 | (42,847,513) | (1,574,556) |
Net loss | $ (1,621,546) | ||||
Common stock issued for services (in shares) | 3,162 | ||||
Balance (in shares) at Sep. 30, 2020 | 100 | 3,559,473 | |||
Balance at Sep. 30, 2020 | $ 76,095 | $ 3,559 | 55,203,149 | (44,469,059) | $ 10,813,744 |
Balance (in shares) at Mar. 31, 2020 | 400 | 689,580 | |||
Balance at Mar. 31, 2020 | $ 376,095 | $ 690 | 41,202,172 | (43,443,207) | (1,864,250) |
Net loss | (455,204) | (455,204) | |||
Common stock issued for services (in shares) | 2,124 | ||||
Common stock issued for services | $ 2 | 11,998 | 12,000 | ||
Balance (in shares) at Jun. 30, 2020 | 400 | 691,704 | |||
Balance at Jun. 30, 2020 | $ 376,095 | $ 692 | 41,672,003 | (43,898,411) | (1,849,621) |
Conversion of preferred stock to common stock (in shares) | (300) | 42,723 | |||
Conversion of preferred stock to common stock | $ (300,000) | $ 43 | 299,957 | ||
Net loss | (570,648) | (570,648) | |||
Common stock issued for services (in shares) | 517 | ||||
Common stock issued for services | 6,000 | 6,000 | |||
Balance (in shares) at Sep. 30, 2020 | 100 | 3,559,473 | |||
Balance at Sep. 30, 2020 | $ 76,095 | $ 3,559 | $ 55,203,149 | $ (44,469,059) | $ 10,813,744 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (1,621,546) | $ (1,780,036) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 2,983 | 5,693 |
Stock-based compensation expense | 24,000 | 290,744 |
Changes in assets and liabilities: | ||
Grant funds and other receivables | (72,551) | 18,329 |
Prepaid expenses and other current assets | 82,274 | (83,637) |
Amortization of debt discount | 124,185 | |
Accounts payable and accrued expenses | 252,036 | 431,170 |
Total adjustments | 412,927 | 662,299 |
Net cash used in operating activities | (1,208,619) | (1,117,737) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (2,470) | (4,272) |
Net cash used in investing activities | (2,470) | (4,272) |
Cash flows from financing activities: | ||
Net proceeds from sale of preferred stock | 300,000 | 1,440,000 |
Net proceeds from issuance of note payable | 170,200 | |
Net proceeds from bridge financing | 888,500 | |
Net proceeds from sale of common stock and warrants | 11,158,496 | |
Principal repayment of note payable | (8,854) | (8,333) |
Net cash provided by financing activities | 12,508,342 | 1,431,667 |
Net increase in cash and cash equivalents | 11,297,253 | 309,658 |
Cash and cash equivalents at beginning of period | 283,341 | 259,701 |
Cash and cash equivalents at end of period | $ 11,580,594 | $ 569,359 |
Condensed Consolidated Statem_5
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Cancellation of deferred compensation liability | $ 1,500,000 | |
Stock Issued During Period, Shares, Cancellation of Accrued Compensation | 300,001 | |
Stock Issued During Period, Shares, Warrants Exercised | 36,902 | |
Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member] | ||
Common stock issued upon conversion of preferred stock (in shares) | 716,790 | 2,378 |
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member] | ||
Original amount converted in debt conversion | $ 250,000 | |
Stock issued in conversion of debt (in shares) | 250 | |
Unit Warrants [Member] | ||
Unit warrants issued (in shares) | 300,001 | |
Conversion from Convertible Debentures to Conversion Units [Member] | ||
Accrued interest converted in debt conversion | $ 14,667 | |
Original amount converted in debt conversion | $ 1,200,000 | |
Stock issued in conversion of debt (in shares) | 177,626 | |
Conversion from Convertible Debentures to Conversion Units [Member] | Unit Warrants [Member] | ||
Warrants issued in debt conversion (in shares) | 303,668 | |
Conversion from Convertible Debentures to Conversion Units [Member] | Pre-Funded Warrants [Member] | ||
Warrants issued in debt conversion (in shares) | 126,042 |
Note 1 - Description of Busines
Note 1 - Description of Business | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Nature of Operations [Text Block] | 1. Description of Business GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using a novel vector vaccine platform (Modified Vaccinia Ankara (MVA) Virus-Like Particle, or “GV-MVA-VLP TM Our current development programs are focused on preventive vaccines against novel coronavirus (COVID- 19 Our corporate strategy is to advance, protect and exploit our differentiated vaccine immunotherapy platform leading to the successful development of preventive and therapeutic vaccines against infectious diseases and various cancers. With our design and development capabilities, we are progressing and validating an array of cancer and infectious disease immunotherapy and vaccine product candidates. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area. |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Basis of Accounting [Text Block] | 2. Basis of Presentation The accompanying condensed consolidated financial statements at September 30, 2020 three nine September 30, 2020 2019 not 10 December 31, 2019. not As described in Note 10, April 30, 2019, January 21, 2020 September 30, 2020. Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve For the last several years the audit reports to our consolidated financial statements have included a “going concern” qualification, arising from our limited assets, our history of operating losses, and our continuing need for capital to conduct our research and development activities. These conditions continued through the second 2020. third 2020 10 September 30, 2020 no twelve 2022. We expect to incur future net losses as we continue to fund the development of our product candidates. To date, we have financed our operations primarily with proceeds from sales of equity and debt securities, government grants and clinical trial assistance, and corporate collaborations. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We may may no |
Note 3 - Significant Accounting
Note 3 - Significant Accounting Policies and Recent Accounting Pronouncements | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. Significant Accounting Policies and Recent Accounting Pronouncements We disclosed in Note 2 10 December 31, 2019 no 10 There have been no nine September 30, 2020, 10 December 31, 2019, |
Note 4 - Basic and Diluted Loss
Note 4 - Basic and Diluted Loss Per Common Share | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 4. Basic and Diluted Loss Per Common Share Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, totaled 204,553 78,754 three nine September 30, 2020, 273 272 three nine September 30, 2019, 10 September 30, 2020 |
Note 5 - Property and Equipment
Note 5 - Property and Equipment | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 5. Property and Equipment Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of September 30, 2020 December 31, 2019: September 30, 2020 December 31, 2019 Laboratory equipment $ 537,047 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 664,388 661,918 Accumulated depreciation and amortization (654,295 ) (651,312 ) Property and equipment, net $ 10,093 $ 10,606 |
Note 6 - Accrued Expenses
Note 6 - Accrued Expenses | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 6. Accrued Expenses Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets are composed of the following as of September 30, 2020 December 31, 2019: September 30, 2020 December 31, 2019 Accrued payroll and director fees $ 551,762 $ 1,732,702 Other accrued expenses 27,823 118,338 Total accrued expenses $ 579,585 $ 1,851,040 |
Note 7 - Notes Payable
Note 7 - Notes Payable | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 7. Notes Payable GRA Note – February 28, 2018, five $50,000. 5%, $3,026 2020, $12,487 2021, $13,126 2022, $2,252 2023. three nine September 30, 2020 $411 $1,344, $547 $1,753, 2019. CARES Act Paycheck Protection Program Loan – April 17, 2020, $170,200 one April 17, 2022. November 17, 2020, $9,578.16 may $429 $774 three nine September 30, 2020, October 2020, not |
Note 8 - Convertible Debentures
Note 8 - Convertible Debentures | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Short-term Debt [Text Block] | 8. Convertible Debentures On June 26 2020, two $1,050,000 5% $1,200,000; five “June 2020 120,000 $10.00 $888,500. 10, September 29, 2020 June 2020 $5.00. twelve 5% The Convertible Debentures were mandatorily convertible upon our consummation of a public offering of common stock with gross proceeds of $6,000,000 $10.00 80% not 4.99% On September 29, 2020, 10, $1,200,000 $14,667 $4.00, 303,667 303,668 177,626 one a one 126,042 one one a one $0.01 not one $5.00 five Upon the issuance of the Convertible Debentures, we recorded a debt discount of $769,334, $150,000 $457,834 $161,500 12 September 29, 2020, $645,150 $133,148 138,851 three nine September 30, 2020, $119,139 $124,184, |
Note 9 - Commitments
Note 9 - Commitments | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Commitments Disclosure [Text Block] | 9. Commitments Lease Agreement -- 8,400 December 31, 2022. three nine September 30, 2020 $41,539 $124,617, $40,316 $120,949, 2019. $41,539 2020, $171,213 2021 $176,356 2022, may ninety Other Commitments – September 30, 2020, $290,500 $228,000 2020 $62,500 2021. |
Note 10 - Stockholders' Equity
Note 10 - Stockholders' Equity | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 10. Stockholders' Equity Convertible Preferred Stock We are authorized to issue up to 10,000,000 $.01 may one September 30, 2020 December 31, 2019. $1,000 nine September 30, 2020 September 30, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Total 100 $ 76,095 2,486 $ 1,932,433 As of September 30, 2020, 100 no nine September 30, 2020. During the first 2020, 1,686 469,696 September 30, 2020, no During the first 2020, 700 204,371 September 30, 2020, no On January 24, 2020, 300 $300,000. no not July 2020, 300 42,723 September 30, 2020, no Common Stock Reverse Stock Split s – April 30, 2019, 1 500 January 21, 2020, 1 2000 September 25, 2020, 1 20 Conversions of Preferred Stock nine September 30, 2020, 716,790 Public Offering – September 24, 2020, 2,560,000 September 29, 2020, $12.8 $11.2 Of the 2,560,000 2,310,000 one a one 250,000 a one a one $0.01 not one $5.00 five $5.00 $4.99 45 384,000 Pursuant to the Underwriting Agreement, we issued to the Representative, as a portion of the underwriting compensation, warrants to purchase up to a total of 128,000 $5.50 180 three Conversion of Deferred Compensation to Equity – 2016 2017, September 29, 2020, $1,500,000 $5.00 300,001 one one Conversion of Convertible Debentures to Equity 8, 177,625 126,042 303,667 $1,214,667 Other Common Stock Transactions – nine September 30, 2020, 3,162 Stock Options As a result of the reverse stock splits of our common stock all of our outstanding stock options were automatically adjusted such that all of such stock options as of the beginning of 2020 June 19, 2020, 2020 “2020 250,000 2020 No 2020 nine September 30, 2020. Stock Purchase Warrants Series G Warrants August 2020, no September 30, 2020. Series H Warrants July 2020, 7,147 no September 30, 2020. Series I Warrants July 2020, 29,755 September 30, 2020, 62,626 $5.00 June 2020 8, June 26, 2020, 120,000 five $10.00. September 29, 2020 $5.00. Warrants Issued Upon Conversion of Convertible Debentures 8, September 29, 2020, 126,042 303,668 Warrants Issued Upon Conversion of Deferred Compensation Common Stock – Conversion of Deferred Compensation to Equity September 29, 2020, 300,001 Warrants Issued in Connection with Public Offering Common Stock – Public Offering September 29, 2020, 2,560,000 250,000 128,000 Summary of Warrants Ou tst anding September 30, 2020: Warrant Description Number of Shares Exercise Price Expiration Series I Warrants 62,626 $ 5.00 Oct-Dec 2024 June 2020 Warrants 120,000 5.00 Jun 2025 Pre-Funded Warrants 376,042 0.01 Perpetual Unit, Conversion and Management Warrants 3,163,669 5.00 Sep 2025 Representative Warrants 128,000 5.50 Mar 2024 Total Warrants Outstanding at September 30, 2020 3,850,337 Weighted-Average Exercise Price $ 4.53 Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) 4.9 Stock-Based Compensation Expense There was no three nine September 30, 2020 no September 30, 2020. three nine September 30, 2020 $6,000 $24,000, |
Note 11 - Income Taxes
Note 11 - Income Taxes | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 11. Income Taxes Because of our historically significant net operating losses, we have not 382 |
Note 12 - Grants and Collaborat
Note 12 - Grants and Collaboration Revenue | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Government Grants and Contracts [Text Block] | 12. Grant and Collaboration Revenue We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three nine September 30, 2020, $231,330 $1,186,844, $214,765 $754,022, 2019. September 30, 2020, $417,121 September 2021. During the three nine September 30, 2020, $184,127 $385,193, third $118,444 $153,360, 2019. |
Note 13 - Subsequent Events
Note 13 - Subsequent Events | 9 Months Ended |
Sep. 30, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 13. Subsequent Events During October 2020, 250,000 250,000 $2,500. |
Note 5 - Property and Equipme_2
Note 5 - Property and Equipment (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | September 30, 2020 December 31, 2019 Laboratory equipment $ 537,047 $ 534,577 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 11,736 11,736 Total property and equipment 664,388 661,918 Accumulated depreciation and amortization (654,295 ) (651,312 ) Property and equipment, net $ 10,093 $ 10,606 |
Note 6 - Accrued Expenses (Tabl
Note 6 - Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | September 30, 2020 December 31, 2019 Accrued payroll and director fees $ 551,762 $ 1,732,702 Other accrued expenses 27,823 118,338 Total accrued expenses $ 579,585 $ 1,851,040 |
Note 10 - Stockholders' Equity
Note 10 - Stockholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Notes Tables | |
Schedule of Preferred Stock [Table Text Block] | September 30, 2020 December 31, 2019 Carrying Carrying Shares Value Shares Value Series B Convertible Preferred Stock 100 $ 76,095 100 $ 76,095 Series H Convertible Preferred Stock - - 1,686 1,156,338 Series I Convertible Preferred Stock - - 700 700,000 Total 100 $ 76,095 2,486 $ 1,932,433 |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Warrant Description Number of Shares Exercise Price Expiration Series I Warrants 62,626 $ 5.00 Oct-Dec 2024 June 2020 Warrants 120,000 5.00 Jun 2025 Pre-Funded Warrants 376,042 0.01 Perpetual Unit, Conversion and Management Warrants 3,163,669 5.00 Sep 2025 Representative Warrants 128,000 5.50 Mar 2024 Total Warrants Outstanding at September 30, 2020 3,850,337 Weighted-Average Exercise Price $ 4.53 Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) 4.9 |
Note 4 - Basic and Diluted Lo_2
Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 204,553 | 273 | 78,754 | 272 |
Note 5 - Property and Equipme_3
Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Property and equipment, gross | $ 664,388 | $ 661,918 |
Accumulated depreciation and amortization | (654,295) | (651,312) |
Property and equipment, net | 10,093 | 10,606 |
Laboratory Equipment [Member] | ||
Property and equipment, gross | 537,047 | 534,577 |
Leasehold Improvements [Member] | ||
Property and equipment, gross | 115,605 | 115,605 |
Other Furniture Fixtures And Equipment [Member] | ||
Property and equipment, gross | $ 11,736 | $ 11,736 |
Note 6 - Accrued Expenses - Sch
Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Accrued payroll and director fees | $ 551,762 | $ 1,732,702 |
Other accrued expenses | 27,823 | 118,338 |
Total accrued expenses | $ 579,585 | $ 1,851,040 |
Note 7 - Notes Payable (Details
Note 7 - Notes Payable (Details Textual) - USD ($) | Apr. 17, 2020 | Feb. 28, 2018 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 |
Proceeds from Notes Payable, Total | $ 170,200 | |||||
Long-Term Debt, Maturity, Year One | $ 3,026 | 3,026 | ||||
Paycheck Protection Program CARES Act [Member] | ||||||
Proceeds from Notes Payable, Total | $ 170,200 | |||||
Interest Expense, Debt, Total | 429 | 774 | ||||
Debt Instrument, Periodic Payment, Total | $ 9,578.16 | |||||
Senior Notes [Member] | ||||||
Proceeds from Notes Payable, Total | $ 50,000 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||
Long-Term Debt, Maturity, Year One | 12,487 | 12,487 | ||||
Long-Term Debt, Maturity, Year Two | 13,126 | 13,126 | ||||
Long-Term Debt, Maturity, Year Three | 2,252 | 2,252 | ||||
Interest Expense, Debt, Total | $ 411 | $ 547 | $ 1,344 | $ 1,753 |
Note 8 - Convertible Debentur_2
Note 8 - Convertible Debentures (Details Textual) - USD ($) | Sep. 29, 2020 | Jun. 26, 2020 | Sep. 30, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 24, 2020 |
Proceeds from Convertible Debt | $ 888,500 | |||||
Number of Common Stock Securities Called by Each Unit (in shares) | 1 | |||||
Amortization of Debt Discount (Premium) | 124,185 | |||||
Conversion from Convertible Debentures to Conversion Units [Member] | ||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 4 | |||||
Debt Conversion, Original Debt, Amount | $ 1,200,000 | 1,200,000 | ||||
Debt Conversion, Accrued Interest Amount | $ 14,667 | $ 14,667 | ||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 303,667 | 177,626 | ||||
Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche One [Member] | ||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 177,626 | |||||
Number of Common Stock Securities Called by Each Unit (in shares) | 1 | |||||
Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member] | ||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 126,042 | |||||
June 2020 Warrants [Member] | ||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 120,000 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5 | $ 10 | $ 5 | $ 5 | ||
Warrants and Rights Outstanding | $ 457,834 | |||||
Payments of Debt Issuance Costs | $ 161,500 | |||||
Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche One [Member] | ||||||
Number of Warrants Called by Each Unit (in shares) | 1 | |||||
Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member] | ||||||
Number of Warrants Called by Each Unit (in shares) | 1 | |||||
Conversion Warrant [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||
Pre-Funded Warrants [Member] | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 250,000 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | Conversion Units Tranche Two [Member] | ||||||
Number of Warrants Called by Each Unit (in shares) | 1 | |||||
Unit Warrants [Member] | ||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,560,000 | |||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5 | |||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||
Convertible Debentures [Member] | ||||||
Number of Institutional Investors | 2 | |||||
Proceeds from Convertible Debt, Gross | $ 1,050,000 | |||||
Debt Instrument, Interest Rate, Stated Percentage | 5.00% | |||||
Debt Instrument, Face Amount | $ 1,200,000 | |||||
Proceeds from Convertible Debt | $ 888,500 | |||||
Debt Instrument, Term (Month) | 1 year | |||||
Gross Proceeds from Issuance of Common Stock, Public Offering | $ 6,000,000 | |||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 10 | |||||
Percentage of Offering Price | 80.00% | |||||
Debt Instrument, Convertible, Maximum Allowed Ownership of Common Stock Outstanding, Percentage | 4.99% | |||||
Debt Instrument, Unamortized Discount, Total | $ 645,150 | $ 769,334 | ||||
Debt Conversion, Original Debt Discount | $ 150,000 | |||||
Interest Expense, Debt, Total | $ 133,148 | $ 138,851 | ||||
Amortization of Debt Discount (Premium) | $ 119,139 | $ 124,184 |
Note 9 - Commitments (Details T
Note 9 - Commitments (Details Textual) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020USD ($)ft² | Sep. 30, 2019USD ($) | Sep. 30, 2020USD ($)ft² | Sep. 30, 2019USD ($) | |
Area of Real Estate Property (Square Foot) | ft² | 8,400 | 8,400 | ||
Operating Leases, Rent Expense, Total | $ 41,539 | $ 40,316 | $ 124,617 | $ 120,949 |
Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | 41,539 | 41,539 | ||
Lessee, Operating Lease, Liability, to be Paid, Year One | 171,213 | 171,213 | ||
Lessee, Operating Lease, Liability, to be Paid, Year Two | 176,356 | 176,356 | ||
Unrecorded Unconditional Purchase Obligation, Total | 290,500 | 290,500 | ||
Purchase Obligation, to be Paid, Remainder of Fiscal Year | 228,000 | 228,000 | ||
Purchase Obligation, to be Paid, Year One | $ 62,500 | $ 62,500 |
Note 10 - Stockholders' Equit_2
Note 10 - Stockholders' Equity (Details Textual) | Sep. 29, 2020USD ($)$ / sharesshares | Sep. 25, 2020 | Sep. 24, 2020USD ($)$ / sharesshares | Jan. 24, 2020USD ($)shares | Jan. 21, 2020 | Apr. 30, 2019 | Jul. 31, 2020shares | Sep. 30, 2020USD ($)$ / sharesshares | Mar. 31, 2020shares | Sep. 30, 2020USD ($)$ / sharesshares | Sep. 30, 2019shares | Jun. 26, 2020$ / sharesshares | Dec. 31, 2019$ / sharesshares |
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | 10,000,000 | 10,000,000 | ||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 100 | 100 | 2,486 | ||||||||||
Proceeds from Issuance or Sale of Equity, Gross | $ | $ 12,800,000 | ||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 11,200,000 | ||||||||||||
Number of Common Stock Securities Called by Each Unit (in shares) | 1 | ||||||||||||
Deferred Compensation Liability Conversion to Equity, Amount | $ | $ 1,500,000 | $ 1,500,000 | |||||||||||
Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share) | $ / shares | $ 5 | ||||||||||||
Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares) | 300,001 | 300,001 | |||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 177,625 | ||||||||||||
Stock Issued During Period, Shares, Issued for Services (in shares) | 3,162 | ||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 3,850,337 | 3,850,337 | |||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 36,902 | ||||||||||||
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ | $ 0 | $ 0 | |||||||||||
Stock Issued During Period, Value Expensed During the Period, Issued for Services | $ | 6,000 | 24,000 | |||||||||||
Share-based Payment Arrangement, Option [Member] | |||||||||||||
Share-based Payment Arrangement, Expense | $ | $ 0 | $ 0 | |||||||||||
Stock Incentive Plan 2020 [Member] | |||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance (in shares) | 250,000 | 250,000 | |||||||||||
Conversion from Convertible Debentures to Conversion Units [Member] | |||||||||||||
Debt Conversion, Converted Instrument, Principal and Interest, Amount | $ | $ 1,214,667 | ||||||||||||
Representative [Member] | |||||||||||||
Over-Allotment Option, Term (Day) | 45 days | ||||||||||||
Number of Units Granted for Over-Allotment (in shares) | 384,000 | ||||||||||||
Capital Units [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,560,000 | ||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 5 | ||||||||||||
Conversion Warrants [Member] | |||||||||||||
Class Of Warrant Or Right, Issued During Period (in shares) | 2,560,000 | ||||||||||||
Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | |||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares) | 303,667 | ||||||||||||
Unit Warrant [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | ||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||
Pre-Funded Warrants [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 250,000 | ||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 376,042 | 376,042 | |||||||||||
Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | |||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares) | 126,042 | 126,042 | |||||||||||
Representative Warrants [Member] | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5.50 | $ 5.5 | $ 5.5 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 3 years | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 128,000 | 128,000 | |||||||||||
Class of Warrant or Right, Period for Warrants or Rights Exercisable (Day) | 180 days | ||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 128,000 | 128,000 | |||||||||||
Management Warrant [Member] | |||||||||||||
Number of Warrants Called by Each Unit (in shares) | 1 | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 300,001 | ||||||||||||
Series G Warrants [Member] | |||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | 0 | |||||||||||
Series H Warrants [Member] | |||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | 0 | |||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 7,147 | ||||||||||||
Series I Warrants [Member] | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | $ 5 | |||||||||||
Class of Warrant or Right, Outstanding (in shares) | 62,626 | 62,626 | |||||||||||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 29,755 | ||||||||||||
June 2020 Warrants [Member] | |||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | $ 5 | $ 5 | $ 10 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 120,000 | ||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 120,000 | 120,000 | |||||||||||
Unit Warrants [Member] | |||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 5 | ||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,560,000 | ||||||||||||
Unit Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member] | |||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares) | 303,668 | ||||||||||||
Reverse Stock Split [Member] | |||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 20 | 2,000 | 500 | ||||||||||
Conversion of Series H Preferred Stock Into Common Stock [Member] | |||||||||||||
Conversion of Stock, Shares Converted (in shares) | 1,686 | ||||||||||||
Conversion of Stock, Shares Issued (in shares) | 469,696 | ||||||||||||
Conversion of Series I Preferred Stock Into Common Stock [Member] | |||||||||||||
Conversion of Stock, Shares Converted (in shares) | 700 | ||||||||||||
Conversion of Stock, Shares Issued (in shares) | 204,371 | ||||||||||||
Conversion of Series J Preferred Stock into Common Stock [Member] | |||||||||||||
Conversion of Stock, Shares Converted (in shares) | 300 | ||||||||||||
Conversion of Stock, Shares Issued (in shares) | 42,723 | ||||||||||||
Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member] | |||||||||||||
Conversion of Stock, Shares Issued (in shares) | 716,790 | 2,378 | |||||||||||
Series B Convertible Preferred Stock [Member] | |||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 1,000 | $ 1,000 | $ 1,000 | ||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 100 | 100 | 100 | ||||||||||
Series H Convertible Preferred Stock [Member] | |||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | 1,686 | ||||||||||
Series I Convertible Preferred Stock [Member] | |||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | 700 | ||||||||||
Series J Convertible Preferred Stock [Member] | |||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 0 | |||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 300 | ||||||||||||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ | $ 300,000 | ||||||||||||
Capital Units Tranche One [Member] | Capital Units [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,310,000 | ||||||||||||
Number of Common Stock Securities Called by Each Unit (in shares) | 1 | ||||||||||||
Capital Units Tranche One [Member] | Unit Warrant [Member] | Capital Units [Member] | |||||||||||||
Number of Warrants Called by Each Unit (in shares) | 1 | ||||||||||||
Capital Units Tranche Two [Member] | Capital Units [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 250,000 | ||||||||||||
Capital Units Tranche Two [Member] | Unit Warrant [Member] | Capital Units [Member] | |||||||||||||
Number of Warrants Called by Each Unit (in shares) | 1 | ||||||||||||
Capital Units Tranche Two [Member] | Pre-Funded Warrants [Member] | Capital Units [Member] | |||||||||||||
Number of Warrants Called by Each Unit (in shares) | 1 | ||||||||||||
Units Including Pre-Funded Warrants [Member] | Capital Units [Member] | |||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 4.99 |
Note 10 - Stockholders' Equit_3
Note 10 - Stockholders' Equity - Preferred Stock Summary (Details) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Preferred stock, shares outstanding (in shares) | 100 | 2,486 |
Preferred Stock | $ 76,095 | $ 1,932,433 |
Series B Convertible Preferred Stock [Member] | ||
Preferred stock, shares outstanding (in shares) | 100 | 100 |
Preferred Stock | $ 76,095 | $ 76,095 |
Series H Convertible Preferred Stock [Member] | ||
Preferred stock, shares outstanding (in shares) | 0 | 1,686 |
Preferred Stock | $ 1,156,338 | |
Series I Convertible Preferred Stock [Member] | ||
Preferred stock, shares outstanding (in shares) | 0 | 700 |
Preferred Stock | $ 700,000 |
Note 10 - Stockholders' Equit_4
Note 10 - Stockholders' Equity - Summary of Warrants (Details) - $ / shares | Sep. 30, 2020 | Sep. 29, 2020 | Sep. 24, 2020 | Jun. 26, 2020 |
Number of warrants (in shares) | 3,850,337 | |||
Weighted Average [Member] | ||||
Exercise price (in dollars per share) | $ 4.53 | |||
Series I Warrants [Member] | ||||
Number of warrants (in shares) | 62,626 | |||
Exercise price (in dollars per share) | $ 5 | |||
June 2020 Warrants [Member] | ||||
Number of warrants (in shares) | 120,000 | |||
Exercise price (in dollars per share) | $ 5 | $ 5 | $ 10 | |
Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) (Year) | 5 years | |||
Pre-Funded Warrants [Member] | ||||
Number of warrants (in shares) | 376,042 | |||
Exercise price (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | |
Unit, Conversion and Management Warrants [Member] | ||||
Number of warrants (in shares) | 3,163,669 | |||
Exercise price (in dollars per share) | $ 5 | |||
Representative Warrants [Member] | ||||
Number of warrants (in shares) | 128,000 | |||
Exercise price (in dollars per share) | $ 5.5 | $ 5.50 | ||
Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) (Year) | 3 years | |||
Outstanding Warrants Excluding Pre-Funded Warrants [Member] | Weighted Average [Member] | ||||
Weighted-Average Remaining Life (excluding Pre-Funded Warrants)(in years) (Year) | 4 years 328 days |
Note 11 - Income Taxes (Details
Note 11 - Income Taxes (Details Textual) $ in Thousands | 9 Months Ended |
Sep. 30, 2020USD ($) | |
Income Taxes Paid | $ 0 |
Note 12 - Grants and Collabor_2
Note 12 - Grants and Collaboration Revenue (Details Textual) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Revenue from Contract with Customer, Including Assessed Tax | $ 415,458 | $ 333,209 | $ 1,572,037 | $ 907,382 |
Unused Grant Funds | 417,121 | 417,121 | ||
NIH Grants [Member] | ||||
Revenue from Contract with Customer, Including Assessed Tax | 231,330 | 214,765 | 1,186,844 | 754,022 |
Research Agreements [Member] | ||||
Revenue from Contract with Customer, Including Assessed Tax | $ 184,127 | $ 118,444 | $ 385,193 | $ 153,360 |
Note 13 - Subsequent Events (De
Note 13 - Subsequent Events (Details Textual) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended |
Oct. 31, 2020 | Sep. 30, 2020 | Sep. 30, 2020 | |
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 36,902 | ||
Stock Issued During Period, Value, Warrants Exercised | |||
Stock Issued During Period, Value, New Issues | $ 11,158,496 | ||
Subsequent Event [Member] | |||
Stock Issued During Period, Value, Warrants Exercised | $ 250,000 | ||
Stock Issued During Period, Value, New Issues | $ 2,500 | ||
Subsequent Event [Member] | Pre-Funded Warrants [Member] | |||
Stock Issued During Period, Shares, Warrants Exercised (in shares) | 250,000 |